Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M151,660Revenue $M12,927Net Margin (%)31.9Altman Z-Score17.2
Enterprise Value $M148,068EPS $1.5Operating Margin %40.5Piotroski F-Score8
P/E(ttm)34.0Beneish M-Score-2.4Pre-tax Margin (%)40.9Higher ROA y-yY
Price/Book32.010-y EBITDA Growth Rate %18.8Quick Ratio0.7Cash flow > EarningsY
Price/Sales10.95-y EBITDA Growth Rate %19.6Current Ratio1.0Lower Leverage y-yY
Price/Free Cash Flow36.9y-y EBITDA Growth Rate %20.5ROA % (ttm)42.4Higher Current Ratio y-yN
Dividend Yield %1.3PEG1.7ROE % (ttm)82.8Less Shares Outstanding y-yY
Payout Ratio %44.0Shares Outstanding M2,650ROIC % (ttm)110Gross Margin Increase y-yY

Gurus Latest Trades with NVO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVOKen Fisher 2015-03-31 Reduce-0.03%$41.9 - $54.68
($46.05)
$ 57.2324%Reduce 2.91%12,660,235
NVOMario Gabelli 2015-03-31 Reduce$41.9 - $54.68
($46.05)
$ 57.2324%Reduce 0.30%6,700
NVORuane Cunniff 2015-03-31 Reduce$41.9 - $54.68
($46.05)
$ 57.2324%Reduce 0.17%82,050
NVORuane Cunniff 2014-09-30 Reduce-0.02%$43.9 - $49.03
($46)
$ 57.2324%Reduce 52.87%75,642
NVORuane Cunniff 2014-06-30 Reduce-0.02%$42.28 - $46.52
($44.12)
$ 57.2330%Reduce 33.85%160,492
NVORuane Cunniff 2014-03-31 Reduce-0.01%$36.722 - $48.23
($42.37)
$ 57.2335%Reduce 21.98%242,630
NVORuane Cunniff 2013-12-31 Add0.02%$32.72 - $36.952
($34.87)
$ 57.2364%Add 58.71%310,970
NVOTom Gayner 2013-12-31 Reduce$32.72 - $36.952
($34.87)
$ 57.2364%Reduce 0.23%1,106,000
NVOKen Fisher 2013-12-31 Add$32.72 - $36.952
($34.87)
$ 57.2364%Add 0.29%13,553,935
NVOTom Gayner 2013-09-30 Reduce-0.02%$31.67 - $35.236
($33.64)
$ 57.2370%Reduce 1.51%1,108,500
NVORuane Cunniff 2013-09-30 Add$31.67 - $35.236
($33.64)
$ 57.2370%Add 13.12%195,930
NVOMario Gabelli 2013-09-30 Reduce$31.67 - $35.236
($33.64)
$ 57.2370%Reduce 0.58%8,520
NVOKen Fisher 2013-09-30 Add$31.67 - $35.236
($33.64)
$ 57.2370%Add 0.43%13,514,205
NVORuane Cunniff 2013-06-30 Buy 0.04%$30.11 - $35.326
($33.29)
$ 57.2372%New holding173,200
NVOKen Fisher 2013-06-30 Add0.01%$30.11 - $35.326
($33.29)
$ 57.2372%Add 0.92%13,456,455
NVOTom Gayner 2013-06-30 Reduce-0.01%$30.11 - $35.326
($33.29)
$ 57.2372%Reduce 0.57%1,125,500
NVOMario Gabelli 2013-06-30 Reduce$30.11 - $35.326
($33.29)
$ 57.2372%Reduce 1.15%8,570
NVOTom Gayner 2013-03-31 Reduce-0.01%$32.24 - $38.86
($34.97)
$ 57.2364%Reduce 0.40%1,132,000
NVOMario Gabelli 2013-03-31 Reduce$32.24 - $38.86
($34.97)
$ 57.2364%Reduce 60.32%8,670
NVOKen Fisher 2013-03-31 Add$32.24 - $38.86
($34.97)
$ 57.2364%Add 0.11%13,333,185
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVO is held by these investors:


News about NVO:

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE May 03 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
Additional Changes to the Nintai Portfolio Apr 08 2015 
Probability and Magnitude in Investing Apr 02 2015 
Nintai Returns: Q1 2015 Apr 01 2015 
These High-Quality European Dividend Payers Could Benefit From A Rising Dollar Mar 18 2015 
To Reinvest or Not Reinvest: That is the Question Feb 19 2015 
Guru Stocks at 52-Week Lows: BABA, NVO, PCLN, ING, EMR Feb 09 2015 
Examining The Three Largest Guru Portfolios Oct 24 2014 
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 

More From Other Websites
Hemophilia market will see production rise as Novo Nordisk invest US$225mn in new plant May 25 2015
Novo Nordisk's Saxenda Delays Onset of Type II Diabetes - Analyst Blog May 25 2015
Treatment with Saxenda® for three years reduced the risk of developing type 2 diabetes compared... May 22 2015
Novo Nordisk A/S: Behandling med Saxenda® i tre år nedsætter risikoen for at udvikle type... May 22 2015
Novo Nordisk A/S: Behandling med Saxenda® i tre år nedsætter risikoen for at udvikle type... May 22 2015
Business Highlights May 21 2015
Novo Nordisk, Baxter clash over haemophilia drug patent May 20 2015
Novo Nordisk rejects Baxter patent claim over Novoeight May 20 2015
China Diabetes Management Devices Market Growth to be Driven by Rise in Sedentary Lifestyle and Life... May 20 2015
Novo Nordisk weighs diabetes drug's use in fatty liver disease May 18 2015
Billionaire Jim Simons’ Top Holdings: Amazon.com Inc. (AMZN), Colgate-Palmolive Company and More May 17 2015
UnitedHealth Group (UNH), Novo Nordisk (NVO), Johnson & Johnson (JNJ): Cheapest Healthcare Stocks... May 14 2015
Novo Nordisk A/S - Share repurchase programme May 11 2015
Hot Drugs Show Sharp Price Hikes in Shadow Market May 06 2015
Healthcare Mid-Day Winners and Losers: May 05, 2015 May 05 2015
Healthcare AM Winners and Losers: May 05, 2015 May 05 2015
Healthcare AM Winners and Losers: May 04, 2015 May 05 2015
Healthcare Mid-Day Winners and Losers: May 04, 2015 May 05 2015
Healthcare Winners and Losers: May 04, 2015 May 05 2015
Novo Nordisk (NVO) Beats on Q1 Earnings, Updates Outlook - Analyst Blog May 04 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

Gintaras58
ReplyGintaras58 - 1 year ago
few excellent prducts to come soon
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK